Dr Deshpande's pioneering research on cell-free DNA testing in heart transplants, supported by NIH, aims to detect organ rejection non-invasively. The multi-site clinical validation using the PROSPERA assay, has shown strong performance metrics in detecting acute rejection in both adult and pediatric cohorts. Noninvasive dd-cfDNA technology such as ProsperaTM may reduce the need for surveillance biopsies and enhance the standard of post-transplant care. | Research Features